Registration and abstract submission are open for MS Frontiers conference!
This year the MS Society are hosting their MS research conference at the University of Liverpool.
Find out all about it and how to register via their website:
https://t.co/aFn1eHapik
Fantastic workshop @MRCCTU this week sharing and learning from the experiences of other #MAMS#trials including @EJS_ACT_PD@OctopusTrial@mndsmart followed by another inspiring session led by our brilliant rising stars of the #acord fellows academy 👏🏾
Registration and abstract submission are open for MS Frontiers conference!
This year the MS Society are hosting their MS research conference at the University of Liverpool.
Find out all about it and how to register via their website:
https://t.co/aFn1eHapik
It's gone GLOBAL!
https://t.co/NzWZeMOmFI
Platypus is the Australian extension of OCTOPUS, anyone with Progressive MS can sign up via the same registration of interest portal to take part:
https://t.co/yMtXie2btM
Great Investigator Meeting with our fantastic colleagues across the UK! Talks all about the outstanding work that's gone into setting up and starting the OCTOPUS trial, and the exciting plans moving forwards! @mssocietyuk @MRCCTU
Part 1/4: Professor Chataway speaks with the Trails Talk team about MS, why we need MAMS trials for PMS, and how the OCTOPUS trial was designed
https://t.co/AnHmduNzOf
🚨Exciting news! Our latest podcast mini-series is here and it's all about @OctopusTrial🐙
Octopus is funded by @mssocietyuk to test new treatments for progressive #MultipleSclerosis.
Episode 1 covers the current #MS research landscape.
Listen now🎧👉https://t.co/hGtkcUcJpj
Designing a MAMS trial with binary outcome? Want to optimise it? Need accurate trial timelines, based on realistic assumptions? Then read our article & use latest additions to the nstage software:
https://t.co/kePvWVXj3p
@MaxParmarMRCUCL
@MRCCTU
@UKCTUNetwork@SCTorg@ICTM_UCL
Long-term treatment with anti-CD20 mAbs - is it feasible? What are the risks? From Emma Tallantyre, MD, PhD, Cardiff University, Cardiff, UK. https://t.co/S01qu6VuXb
Excellent @EANeurology#EAN2023 update on our expanded knowledge of #MS CNS compartmentalised inflammation and the exciting near future of BTK Inhibitors by Wallace Brownlee, Veronica Popescu and Martin König
@DrWBRO @VeroPopescu
What is MS progression? Our understanding of progress independent of disease activity (PIRA) has grown over the last 20 years, with clinical and real world studies confirming that once relapses are controlled with DMTs progression can still happen!
An excellent overview of #SMOULDERINGMS - how we see progression independent of relapses #PIRA, what processes are involved and what #biomarkers will let us ultimately lead to individualized treatment!
#BrainAtrophy and #CognitiveImpairment in #MS - Closely interlinked, and of great importance to PWMS. Cognitive impairment being associated with more care needs and worse quality of life - focus on slowing/stopping this is essential!
#BigData in #MS - a great overview of the incorporation of all the -omics (genomic, metabolomics, proteomics, etc) towards novel understanding and treatments for #PMS#ProgressiveMS